A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...
Considering the reasons behind the jump in licensing deal values, Chan added: “Licensing agreement deal values for mRNA-based ...
This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.
Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback